Advertisement
Advertisement
RYTM
Rhythm Pharmaceuticals, Inc. Common Stock
89.64
USDSponsored
+1.19
+1.35%
Oct 08, 15:59 UTC -4
Closed
After-Market
89.59
-0.05
-0.06%
RYTM Earnings Reports
Positive Surprise Ratio
RYTM beat 20 of 36 last estimates.
56%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$85.65M
/-$0.73
Implied change from Q2 26 (Revenue/ EPS)
+20.20%
/--
Implied change from Q3 25 (Revenue/ EPS)
+66.96%
/-10.98%
Rhythm Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Aug 04, 2026, RYTM reported earnings of -0.73 USD per share (EPS) for Q2 26, beating the estimate of -0.83 USD, resulting in a 12.85% surprise. Revenue reached 71.25 million, compared to an expected 68.62 million, with a 3.84% difference. The market reacted with a +2.92% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.73 USD, with revenue projected to reach 85.65 million USD, implying an increase of 0.00% EPS, and increase of 20.20% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nanobiotix S.A. - ADR
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.70
Surprise
-496.76%
Inventiva S.A. - ADR
Report Date
Sep 28, 2026 For Q2 26
Estimate
-$0.37
Actual
-$0.25
Surprise
+33.55%
Rezolute, Inc. Common Stock (NV)
Report Date
Sep 24, 2026 For Q4 26
Estimate
-$0.15
Actual
-$0.20
Surprise
-32.45%
Palatin Technologies, Inc. Common Stock
Report Date
Sep 28, 2026 For Q4 26
Estimate
-$1.21
Actual
-$1.11
Surprise
+8.42%
NeuroSense Therapeutics Ltd. Ordinary Shares
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$3.26
Actual
-$2.10
Surprise
+35.66%
FAQ
What were Rhythm Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Rhythm Pharmaceuticals, Inc. Common Stock reported EPS of -$0.73, beating estimates by 12.85%, and revenue of $71.25M, 3.84% above expectations.
How did the market react to Rhythm Pharmaceuticals, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 2.92%, changed from $102.78 before the earnings release to $105.78 the day after.
When is Rhythm Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Rhythm Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on --
analysts, Rhythm Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.73 and revenue of $85.65M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.